Susan Halabi

Overview:

Design and analysis of clinical trials, statistical analysis of biomarker and high dimensional data, development and validation of prognostic and predictive models.

Positions:

Professor of Biostatistics and Bioinformatics

Biostatistics & Bioinformatics
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

Ph.D. 1994

University of Texas Health Sciences Center at Houston

Grants:

Prognostic Models of Clinical Outcomes In Men With Castration Resistant Prostate Cancer

Administered By
Biostatistics & Bioinformatics
Awarded By
National Institutes of Health
Role
Principal Investigator
Start Date
End Date

Surrogate Endpoints of Overall Survival in Men with Metastatic Hormone Sensitive Prostate Cancer

Administered By
Biostatistics & Bioinformatics
Role
Principal Investigator
Start Date
End Date

Precision Medicine in Platinum-treated Lethal Bladder Cancer

Administered By
Biostatistics & Bioinformatics
Awarded By
Memorial Sloan Kettering Cancer Center
Role
Principal Investigator
Start Date
End Date

Serum Androgens and Survival in CRPC

Administered By
Duke Cancer Institute
Awarded By
University of California, San Francisco
Role
Principal Investigator
Start Date
End Date

Admin Suppl to Study Mechanisms of Ca Sensitivity and Resistance... CALGB 90203

Administered By
Duke Cancer Institute
Awarded By
Brigham and Women's Hospital
Role
Principal Investigator
Start Date
End Date

Publications:

Androgen decline and outcome in castration resistant prostate cancer (mCRPC) patients treated with docetaxel (Doc), prednisone plus /- bevacizumab (B)

Authors
Ryan, CJ; Dutta, S; Kelly, W; Morris, MJ; Taplin, M-E; Halabi, S
MLA Citation
URI
https://scholars.duke.edu/individual/pub1373858
Source
wos
Published In
Annals of Oncology
Volume
29
Published Date
Start Page
283
End Page
283

Progression-free survival (PFS) by independent review and updated overall survival (OS) results from Alliance A031203 trial (CABOSUN): Cabozantinib versus sunitinib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC)

Authors
Choueiri, TK; Hessel, C; Halabi, S; Sanford, B; Hahn, O; Michaelson, MD; Walsh, M; Olencki, T; Picus, J; Small, EJ; Dakhil, S; Scheffold, C; George, DJ; Morris, MJ
URI
https://scholars.duke.edu/individual/pub1279421
Source
wos
Published In
Annals of Oncology
Volume
28
Published Date

Abstract 2037: A discovery study to identify clinical and genetic risk factors for bevacizumab (BEV)-related gastrointestinal (GI) hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated on CALGB 90401 (Alliance)

Authors
Patel, JN; Jiang, C; Owzar, K; Hertz, DL; Mulkey, FA; Kelly, WK; Halabi, S; Furukawa, Y; Lassiter, C; Dorsey, SG; Friedman, PN; Small, EJ; Carducci, MA; Mahoney, JF; Kelley, MJ; Nakamura, Y; Kubo, M; Ratain, MJ; Morris, MJ; McLeod, HL
MLA Citation
URI
https://scholars.duke.edu/individual/pub1169614
Source
crossref
Published In
Experimental and Molecular Therapeutics
Published Date
DOI
10.1158/1538-7445.am2016-2037

Final clinical results of a randomized phase II international trial of everolimus vs. sunitinib in patients with metastatic non-clear cell renal cell carcinoma (ASPEN)

Authors
Armstrong, AJ; Broderick, S; Eisen, T; Stadler, WM; Jones, RJ; Garcia, JA; Vaishampayan, UN; Picus, J; Hawkins, RE; Hainsworth, JD; Kollmannsberger, CK; Logan, TF; Puzanov, I; Pickering, LM; Ryan, CW; Protheroe, A; Lusk, CM; Oberg, S; Halabi, S; George, DJ
MLA Citation
Armstrong, Andrew J., et al. “Final clinical results of a randomized phase II international trial of everolimus vs. sunitinib in patients with metastatic non-clear cell renal cell carcinoma (ASPEN).” Journal of Clinical Oncology, vol. 33, no. 15, AMER SOC CLINICAL ONCOLOGY, 2015.
URI
https://scholars.duke.edu/individual/pub1085413
Source
wos
Published In
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Volume
33
Published Date

Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance).

PURPOSE: Zoledronic acid decreases the risk for skeletal-related events (SREs) in men with castration-resistant prostate cancer and bone metastases but its role earlier in the natural history of the disease is unknown. This phase III study evaluated the efficacy and safety of earlier treatment with zoledronic acid in men with castration-sensitive metastatic prostate cancer. PATIENTS AND METHODS: Men with castration-sensitive prostate cancer and bone metastases whose androgen-deprivation therapy was initiated within 6 months of study entry were randomly assigned in a blinded 1:1 ratio to receive zoledronic acid (4 mg intravenously every 4 weeks) or a placebo. After their disease progressed to castration-resistant status, all patients received open-label treatment with zoledronic acid. The primary end point was time to first SRE, defined as radiation to bone, clinical fracture, spinal cord compression, surgery to bone, or death as a result of prostate cancer. Target accrual was 680 patients. Primary analysis was planned after 470 SREs. The study was discontinued prematurely (645 patients; 299 SREs) after the corporate supporter withdrew study drug supply. RESULTS: Early zoledronic acid was not associated with increased time to first SRE. The median time to first SRE was 31.9 months in the zoledronic acid group (95% CI, 24.2 to 40.3) and 29.8 months in the placebo group (95% CI, 25.3 to 37.2; hazard ratio, 0.97; 95% CI, 0 to 1.17; one-sided stratified log-rank P = .39). Overall survival was similar between the groups (hazard ratio, 0.88; 95% CI, 0.70 to 1.12; P = .29). Rates of adverse events were similar between the groups. CONCLUSION: In men with castration-sensitive prostate cancer and bone metastases, early treatment with zoledronic acid was not associated with lower risk for SREs.
Authors
Smith, MR; Halabi, S; Ryan, CJ; Hussain, A; Vogelzang, N; Stadler, W; Hauke, RJ; Monk, JP; Saylor, P; Bhoopalam, N; Saad, F; Sanford, B; Kelly, WK; Morris, M; Small, EJ
MLA Citation
Smith, Matthew R., et al. “Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance)..” J Clin Oncol, vol. 32, no. 11, Apr. 2014, pp. 1143–50. Pubmed, doi:10.1200/JCO.2013.51.6500.
URI
https://scholars.duke.edu/individual/pub1023916
PMID
24590644
Source
pubmed
Published In
Journal of Clinical Oncology
Volume
32
Published Date
Start Page
1143
End Page
1150
DOI
10.1200/JCO.2013.51.6500

Research Areas:

Adenocarcinoma
Adenocarcinoma, Clear Cell
African Americans
Age Factors
Aged, 80 and over
Alkaline Phosphatase
Alleles
Arab countries
Area Under Curve
Biological Markers
Biomarkers, Pharmacological
Breast Neoplasms
Cancer Vaccines
Carcinoma
Carcinoma, Renal Cell
Case-Control Studies
Chemoprevention
Chemotherapy
Chi-Square Distribution
Clinical Trials, Phase II as Topic
Clinical trials
Cohort Studies
Computer Simulation
Confidence Intervals
Construction Materials
Contraceptives, Oral
DNA Damage
DNA Primers
DNA Repair
DNA, Neoplasm
Data Interpretation, Statistical
Decision Making
Decision Support Techniques
Diagnostic Imaging
Disease Progression
Disease-Free Survival
Drug Design
Dust
Efficiency, Organizational
Endpoint Determination
Equipment Design
Factor Analysis, Statistical
Family relationships
Gels
Gene Expression
Genes, Immunoglobulin
Genetic Predisposition to Disease
Genetics, Medical
Genotype
Germany
Graft vs Host Disease
HIV Infections
Hispanic Americans
Individualized Medicine
Kaplan-Meier Estimate
Ketoconazole
Lasso
Logistic Models
Lymphokines
Mining
Models, Biological
Models, Statistical
Models, Theoretical
Molecular Sequence Data
Multiprotein Complexes
Multivariate Analysis
Mutation
Neoplasms, Hormone-Dependent
Nomograms
Odds Ratio
Outcome Assessment (Health Care)
Ovarian Neoplasms
Personalized medicine
Population
Population Surveillance
Precision Medicine
Predictive Value of Tests
Pregnancy
Probability
Prognosis
Proportional Hazards Models
Prospective Studies
ROC Curve
Randomized Controlled Trials as Topic
Receptors, Progesterone
Registries
Reproducibility of Results
Research Design
Residence Characteristics
Retrospective Studies
Ribosomal Protein S6 Kinases
Risk
Risk Assessment
Risk Factors
Sample Size
Selective Estrogen Receptor Modulators
Sensitivity and Specificity
Statistics as Topic
Survival
Survival Analysis
Survival Rate
Tamoxifen
Translocation, Genetic
Treatment Failure
Treatment Outcome
Tumor Markers, Biological
United States
Urologic Neoplasms
Validation Studies as Topic
Vascular Endothelial Growth Factors